Biomarker Research Services Market, By Service Type (Biomarker Research Services and Companion Diagnostics (CDx) Research Services), By Disease Indication (Cancer, Cardiovascular Disorders, Infectious Diseases, Neurological Disorders, Immunological Disorders, and Others), By End User (Hospitals, Diagnostic Centers, Specialty Centers, and Research Institutions), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa).

Published In : Dec 2024

Code : CMI2612

Pages :178

Formats :

Excel and PDF

Industry : Biotechnology

Regional Analysis

Biomarker Research Services Market Regional Insights

To learn more about this report, Request sample copy

Dominating Region: North America

North America dominates the biomarker research services market with a share of 38.2% in 2024, which can be attributed to robust research investments by pharmaceutical companies and presence of leading contract research organization in the region. Stringent regulations have also boosted clinical trial activities, providing a fillip to biomarker discovery and validation studies.

Fastest-Growing Region: Asia Pacific

Asia Pacific region exhibits the fastest growth led by China, Japan, and India. Government support for healthcare research and increasing willingness of pharmaceutical companies to offshore biomarker related work to the region are driving the market. A large patient population and high disease burden have further accelerated clinical research in Asia Pacific.

Biomarker Research Services Market Outlook for Key countries

Leading European Biomarker Research with R&D and Collaborations in Germany

Germany is emerging as a leader in the biomarker research services market, driven by significant R&D investments in biotechnology. The country’s robust healthcare system and supportive policies for innovation in diagnostics contribute to market growth. In April 2020, recent advancements include collaborations between biotech firms like BioNTech and research institutions.

Driving Biomarker Drug Development through Industry Consolidation in the U.S.

The U.S. biomarker research services market remains driven by consolidation among pharmaceutical companies and expanding biomarker-based drug development pipelines. Important players like IQVIA and Laboratory Corporation of America Holdings are contributing to the market growth.

Expanding Biomarker Research with Government Investment in China

China’s biomarker research services market is rapidly expanding, driven by increasing healthcare expenditures and a growing patient population. In December 2023, the Chinese government announced a US$ 500 million investment in biotechnology research, specifically targeting biomarker development for cancer diagnostics. This initiative underscores the country's commitment to advancing healthcare technologies

Advancing Biomarker Research for Precision Medicine in Japan

The Japan market for biomarker research services is fueled by its aging population and increasing demand for precision medicine. In June 2024, recent developments include partnerships between pharmaceutical companies like Takeda and research organizations to develop biomarker-based therapies.